STING1 and autoimmune interstitial lung disease-arthritis syndrome: Therefore, our study provides hope that targeting the cGAS/STING pathway directly, for example with a STING inhibitor such as H-151, may be more specific and thus proves a greater beneficial approach to control type I IFN-mediated symptoms in COPA syndrome.